438 related articles for article (PubMed ID: 15497675)
1. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.
van Raalte DH; Li M; Pritchard PH; Wasan KM
Pharm Res; 2004 Sep; 21(9):1531-8. PubMed ID: 15497675
[TBL] [Abstract][Full Text] [Related]
2. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Han SH; Quon MJ; Koh KK
Hypertension; 2005 Nov; 46(5):1086-92. PubMed ID: 16230515
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
Fruchart JC; Duriez P; Staels B
Curr Opin Lipidol; 1999 Jun; 10(3):245-57. PubMed ID: 10431661
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
5. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352
[TBL] [Abstract][Full Text] [Related]
6. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
7. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis.
Pruimboom-Brees I; Haghpassand M; Royer L; Brees D; Aldinger C; Reagan W; Singh J; Kerlin R; Kane C; Bagley S; Hayward C; Loy J; O'Brien P; Francone OL
Am J Pathol; 2006 Sep; 169(3):750-60. PubMed ID: 16936252
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.
Gouni-Berthold I; Krone W
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):513-23. PubMed ID: 16503871
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?
Puddu P; Puddu GM; Muscari A
Int J Cardiol; 2003 Aug; 90(2-3):133-40. PubMed ID: 12957742
[TBL] [Abstract][Full Text] [Related]
11. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
12. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
Neve BP; Fruchart JC; Staels B
Biochem Pharmacol; 2000 Oct; 60(8):1245-50. PubMed ID: 11007963
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis.
Yu XH; Zheng XL; Tang CK
Adv Clin Chem; 2015; 71():171-203. PubMed ID: 26411415
[TBL] [Abstract][Full Text] [Related]
14. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
15. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.
Israelian-Konaraki Z; Reaven PD
Cardiology; 2005; 103(1):1-9. PubMed ID: 15528894
[TBL] [Abstract][Full Text] [Related]
17. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions.
Yoon M
Pharmacol Res; 2009 Sep; 60(3):151-9. PubMed ID: 19646654
[TBL] [Abstract][Full Text] [Related]
18. Factors modulating fibrates response: therapeutic implications and alternative strategies.
Panadero MI; González MC; Herrera E; Bocos C
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):219-36. PubMed ID: 19594420
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes.
Ribet C; Montastier E; Valle C; Bezaire V; Mazzucotelli A; Mairal A; Viguerie N; Langin D
Endocrinology; 2010 Jan; 151(1):123-33. PubMed ID: 19887568
[TBL] [Abstract][Full Text] [Related]
20. Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.
Colin S; Briand O; Touche V; Wouters K; Baron M; Pattou F; Hanf R; Tailleux A; Chinetti G; Staels B; Lestavel S
Eur Heart J; 2013 Aug; 34(32):2566-74. PubMed ID: 22843443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
